IDEA Collider: Innovation & Asymmetric Learning in Pharma

With so much at stake in the application of AI/ Machine Learning to pharma, biotech and medicine, this wonderful book touches on biases, systems of learning, and the choices we have to make to properly harness the power of what is possible. Email mike at ideapharma.com to enter a lottery to win a copy of the hardcover book, closing date 26th February.From the page at brianchristian.org: A jaw-dropping exploration of everything that goes wrong when we build AI systems and the movement to fix them. Today’s “machine-learning” systems, trained by data, are so effective that we’ve invited them to see and hear for us—and to make decisions on our behalf. But alarm bells are ringing. Recent years have seen an eruption of concern as the field of machine learning advances. When the systems we attempt to teach will not, in the end, do what we want or what we expect, ethical and potentially existential risks emerge. Researchers call this the alignment problem. Systems cull résumés until, years later, we discover that they have inherent gender biases. Algorithms decide bail and parole—and appear to assess Black and White defendants differently. We can no longer assume that our mortgage application, or even our medical tests, will be seen by human eyes. And as autonomous vehicles share our streets, we are increasingly putting our lives in their hands. The mathematical and computational models driving these changes range in complexity from something that can fit on a spreadsheet to a complex system that might credibly be called “artificial intelligence.” They are steadily replacing both human judgment and explicitly programmed software. In best-selling author Brian Christian’s riveting account, we meet the alignment problem’s “first-responders,” and learn their ambitious plan to solve it before our hands are completely off the wheel. In a masterful blend of history and on-the ground reporting, Christian traces the explosive growth in the field of machine learning and surveys its current, sprawling frontier. Readers encounter a discipline finding its legs amid exhilarating and sometimes terrifying progress. Whether they―and we―succeed or fail in solving the alignment problem will be a defining human story. The Alignment Problem offers an unflinching reckoning with humanity’s biases and blind spots, our own unstated assumptions and often contradictory goals. A dazzlingly interdisciplinary work, it takes a hard look not only at our technology but at our culture―and finds a story by turns harrowing and hopeful. Read more at: https://brianchristian.org/the-alignment-problem/

 Syn is an award winning music agency and creative solutio, providing music strategy, composition, sound design and sonic branding for advertising, cinema and television, as well as music supervision, licensing and music curation services and our studios record voiceover, ADR and narration.In this interview, we discuss the user experience (patient, physician), via sound, for healthcare and pharma environmentsMore information at https://syn.world

Great interview with Riccardo on CNBCFind out more about PTEN Research at https://www.ptenresearch.org

Covering a wide variety of topics, with a special focus on Novartis as one of the best examples of a learning organisation in pharma. On cultures of innovation, 'unbossing', decision making and measuring what matters John can be found on LinkedIn: https://www.linkedin.com/in/john-tsai-md-ab398b4/ or contacted by email at john_tsai.office at novartis.com

A discussion of The Playbook, from DiMe Society, Digital Clinical Measures Introducing the essential industry guide for successfully developing & deploying digital clinical measures across clinical research, clinical care, and public health https://playbook.dimesociety.org More on Andy (Andrea) Coravos here: http://www.andreacoravos.com More on Jen (Jennifer) Goldsack here: https://en.wikipedia.org/wiki/Jennifer_Goldsack More on DiMe Society here: https://www.dimesociety.org

Carinne Brouillon is a Member of the Board of Managing Directors, with responsibility for the Human Pharma Business Unit Professional milestones 2018 – 2019 Global Head of Therapeutic Areas, Boehringer Ingelheim 2014 – 2018 Head of Global Commercial Strategy Neuroscience at Janssen, Johnson & Johnson’s Pharmaceutical Company 2012 – 2018 President of Janssen Therapeutics and Member of the Janssen North America Leadership Team Edward Hæggström Born 1969. Finnish citizen. Co-founder of Nanoform, CEO and a member of the Management Team since 2015. Education: Ph.D. degree in applied physics from the University of Helsinki and a Master of Business Administration degree in innovation management from Helsinki University of Technology. Experience: Dr. Hæggström has, among others, been a professor at the University of Helsinki and Head of the Electronics Research Laboratory within the Department of Physics. He has previously held the role of visiting professor of physics at Harvard Medical School, visiting scholar (assistant professor) of physics at Stanford University and project leader at the CERN. Rob Scott, MD, a trained physician, has held leadership positions in global pharmaceutical companies for thirty years. During his career he has managed drug development teams responsible for highly successful pharmaceutical brands such as Norvasc, Lipitor, Repatha, Humira, Skyrizi and Rinvoq. Before retiring, his most recent position was Chief Medical Officer and Head of Development at AbbVie where he had oversight on all early and late-stage development programs. He was also responsible for a team of over 4,000 employees spanning 52 countries, a budget of close to $2 billion and programs involving approximately 40 new molecular entities. Before that, he was Vice President, Global Development TA Head and Head of Development Design Center at Amgen where he was responsible for the development of evolocumab (Repatha) the first approved PCSK9 inhibitor, ivabradine (Corlanor), to treat heart failure and omecamtiv mecarbil, a direct myosin activator for heart failure. From 2012 - 2016 he was a member of the US Food and Drug Administration’s Cardiovascular and Renal Drug Advisory Committee where he built strong relationships with senior FDA staff. Before Amgen, he held several leadership positions with emerging pharmaceutical and biotech companies. Dr. Scott is a graduate from the University of Cape Town, South Africa and started his career at Janssen as a Medical Advisor. He is a board member of Transclerate and a member of the PhRMA R&D Leadership Forum.

This episode replays some of a round table we held at JP Morgan, back when people used to travel... It features the voices of Mike Rea, in conversation with Linda Avey, Co-founder of 23andMe, and Curious, Inc, Amrit Chaudhuri, CEO, Mass Innovation Labs (now SmartLabs), Steve Holtzman, then CEO, Decibel Therapeutics, Raj Kannan then SVP, Global Franchise Head, Neurology & Immunology, EMD Serono, Michael Schrage, Research Fellow, MIT Center for Digital Business; Visiting Fellow, Imperial College Department of Innovation and Entrepreneurship, and Robert Urban, then Global Head, Johnson & Johnson Innovation Do head to our YouTube channel for more from this round table, and to see which voice belongs to which speaker...

ABOUT THE INNOVATION DELUSION Innovation is the hottest buzzword in business. But what if our obsession with finding the next big thing has distracted us from the work that matters most? “The most important book I’ve read in a long time . . . It explains so much about what is wrong with our technology, our economy, and the world, and gives a simple recipe for how to fix it: Focus on understanding what it takes for your products and services to last.”—Tim O’Reilly, founder of O’Reilly Media It’s hard to avoid innovation these days. Nearly every product gets marketed as being disruptive, whether it’s genuinely a new invention or just a new toothbrush. But in this manifesto on thestate of American work, historians of technology Lee Vinsel and Andrew L. Russell argue that our way of thinking about and pursuing innovation has made us poorer, less safe, and—ironically—less innovative. Drawing on years of original research and reporting, The Innovation Delusion shows how the ideology of change for its own sake has proved a disaster. Corporations have spent millions hiring chief innovation officers while their core businesses tank. Computer science programs have drilled their students on programming and design, even though theoverwhelming majority of jobs are in IT and maintenance. In countless cities, suburban sprawl has left local governments with loads of deferred repairs that they can’t afford to fix. And sometimes innovation even kills—like in 2018 when a Miami bridge hailed for its innovative design collapsed onto a highway and killed six people. In this provocative, deeply researched book, Vinsel and Russell tell the story of how we devalued the work that underpins modern life—and, in doing so, wrecked our economy and public infrastructure while lining the pockets of consultants who combine the ego of Silicon Valley with the worst of Wall Street’s greed. The authors offer a compelling plan for how we can shift our focus away from the pursuit of growth at all costs, and back toward neglected activities like maintenance, care, and upkeep. For anyone concerned by the crumbling state of our roads and bridges or the direction our economy is headed, The Innovation Delusion is a deeply necessary reevaluation of a trend we can still disrupt.

Peter B. Bach is a physician, epidemiologist, researcher, and respected healthcare policy expert whose work focuses on the cost and value of anticancer drugs. Dr. Bach is leading efforts to increase understanding of the US drug development process and develop new models for drug pricing that include value to patients Dr. Bach described a 100-fold increase in cancer drug prices since 1965 after adjusting for inflation, and that the cost of an additional year of life from a cancer treatment increases by $8,500 each year. In 2012, he and other physicians at MSK drew attention to the high price of a newly approved cancer drug and announced his hospital’s unprecedented move not to offer it to patients because of its high price tag with no notable improved clinical outcomes. The drug price was later cut in half by the manufacturer. Dr. Bach’s work in lung cancer screening has led to the development of several lung cancer screening guidelines and one of the first-ever risk-prediction models for this disease. He has also proposed a number of strategies for Medicare to link payment to the value of healthcare services delivered. Dr. Bach has been inducted into the National Academy of Medicine, American Society of Clinical Investigators and the Johns Hopkins University Society of Scholars. He served as a Senior Advisor for Cancer Policy at the Center for Medicare and Medicaid Services in 2005 and 2006. Dr. Bach has published more than 100 peer-reviewed articles and editorials in scientific journals such as the New England Journal of Medicine and the Journal of the American Medical Association. He has also written numerous healthcare-related op-eds and been featured in mainstream media outlets such as the New York Times, New York magazine, the Wall Street Journal, Forbes, NPR, and 60 Minutes. View a comprehensive list of media coverage of Dr. Bach and his work. Dr. Bach completed his undergraduate studies at Harvard University and his medical studies at the University of Minnesota and the University of Chicago Harris School. He completed a residency in internal medicine at Johns Hopkins University followed by a fellowship in pulmonary and critical care medicine at the University of Chicago and Johns Hopkins. While at the University of Chicago, he was a Robert Wood Johnson Foundation Clinical Scholar. Dr. Bach has been a faculty member in MSK’s Department of Epidemiology and Biostatistics since 1998 and a Senior Scholar at the International Agency for Research on Cancer since 2008. In 2020, Dr. Bach co-founded EQRx, a biotechnology startup focused on developing affordable drugs. He currently serves an advisory role within the organization. Further information at: https://drugpricinglab.org/about/ or https://www.mskcc.org/news/media-coverage?keys=Peter+bach

In conversation, discussing patient input into clinical programs, unmet need assessments, measurement and so much more.Jen was diagnosed with juvenile arthritis as an infant and now has a laundry list of other conditions and surprises (like a brain tumor). She is passionate about elevating and valuing the patient voice, and went on to become a health outcomes researcher, human factors engineer, FDA Consumer Representative, and, most importantly, a patient advocate. Jen earned a PhD in Environmental Medicine from NYU, and studies patient-centered outcomes at Columbia University Medical Center. Jen can usually be found dodging NYC traffic on her bicycle, sitting next to you at a conference, or rocking out to '90s music - she does a sweet running man.Jen at IDEA's UnHerd event at 2020 JP Morganhttps://medium.com/@jhoronjeffhttps://www.savvy.coophttps://techcrunch.com/2020/02/14/this-co-op-wants-to-put-money-back-into-patients-hands/